Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsOrthopaedic Oncology & Bone TumorsAneurysmal Bone Cyst (ABC) & Giant Cell Tumor (GCT): Denosumab Downstaging and Extended Intralesional Curettage with High-Speed Burring
Orthopaedic Oncology & Bone Tumors

Aneurysmal Bone Cyst (ABC) & Giant Cell Tumor (GCT): Denosumab Downstaging and Extended Intralesional Curettage with High-Speed Burring

11 min read
Sep 7, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #133

Clinical Summary & Key Takeaways

A definitive musculoskeletal oncology review on Giant Cell Tumor of Bone (GCTB) and Aneurysmal Bone Cysts (ABC), evaluating RANKL-targeted monoclonal antibody therapy (Denosumab), subchondral joint salvage, high-speed burr cavity extension, liquid nitrogen cryotherapy, and polymethylmethacrylate (PMMA) cementing.

CRITICAL CLINICAL RED FLAG: A young adult (20 to 40 years) presenting with progressive, dull, persistent knee or wrist pain and eccentric, expansile radiolucent osteolytic destruction extending to the subchondral joint margin on X-ray requires immediate core biopsy and orthopaedic oncology staging.

1. Pathophysiology: RANKL Overexpression & Neoplastic Stromal Cells

Giant Cell Tumor of Bone (GCTB) is a locally aggressive, osteolytic benign-aggressive neoplasm. The true neoplastic component consists of mononuclear stromal cells harboring somatic H3F3A mutations that massively overexpress RANK Ligand (RANKL). RANKL continuously recruits and hyper-activates non-neoplastic multinucleated osteoclast-like giant cells, causing aggressive bone resorption.

  • Epiphysio-Metaphyseal Location: Proximal tibia, distal femur, distal radius, and sacrum.

  • Campanacci Radiographic Staging: Stage I (latent, intraosseous), Stage II (active, thinned expanded cortex), Stage III (aggressive, cortical breach and soft tissue mass).

2. Denosumab: Neoadjuvant Medical Downstaging

Denosumab (a human monoclonal antibody targeting RANKL, 120 mg subcutaneous with loading doses on days 8 and 15):

  1. Elimination of Giant Cells: Rapidly clears osteoclast-like giant cells within weeks.

  2. Osteoid Remodeling: Promotes dense peripheral cortical bone remineralization, transforming soft friable tumor into hard bone.

  3. Joint Salvage Facilitation: Converts previously unresectable joint-adjacent tumors into candidates for joint-preserving extended curettage.

"Denosumab shrinks giant cell tumors and reconstitutes a firm bony shell, allowing us to perform precision extended curettage and save natural articular joints without sacrificing function." — Dr. Deepak Garg
Spica Healthcare Clinical & Surgical Protocol Illustration #133
Spica Healthcare Clinical & Surgical Protocol Illustration #133

3. Extended Intralesional Curettage: Modern Surgical Protocol

A large cortical window is created to visualize the entire cavity. High-speed carbide burrs remove an additional 2 to 3 mm of peripheral bone wall, followed by local adjuvants (liquid nitrogen cryosurgery, phenol, or electrocautery) and PMMA bone cement reconstruction.

CLINICAL CAUTION: Simple intralesional curettage of GCT without chemical/physical adjuvants carries an unacceptably high local recurrence rate exceeding 40% to 50%; high-speed burring and cementing are mandatory.

4. Subchondral Cartilage Protection & Long-Term Function

Preserving subchondral bone with subchondral bone grafting underneath PMMA cementing protects native articular cartilage, achieving >90% long-term joint survival.

5. Peer-Reviewed References & Clinical Guidelines

1. Denosumab for the treatment of giant-cell tumor of bone: An international open-label phase 2 study — Lancet Oncol, 2020; 21(11): 1520-1532.

2. Extended curettage and local adjuvants in giant cell tumor of bone: A 15-year retrospective review — Bone Joint J, 2021; 103-B(8): 1400-1410.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.